Shares of Strides Pharma Science plunged 5.6 percent intraday Wednesday after company received three observations from the USFDA.
The formulations facility in Bangalore recently underwent pre- approval product inspection by the USFDA. The inspection ended on August 25, 2018 and the company has been issued a Form 483 with 3 observations.
The company believes that the observations are not material in nature and we have already responded to the USFDA.
The company has recently (post completion of the inspection) received a product approval for Potassium Chloride Extended release tablets from this facility.
At 11:18 hrs Strides Pharma Science was quoting at Rs 475.35, down Rs 23.75, or 4.76 percent on the #BSE.
For Real Time News & Trading Trends Keep Liking Epic Research Limited